Haermonics is a clinical stage medtech company that aims to revolutionize postoperative heart surgery care. With a focus on preventing complications caused by residual blood and clots in the pericardial cavity, Haermonics has developed an innovative flush-therapy solution called the Haermonics Laebroides®. This simple yet highly effective device continuously flushes and cleans the pericardial space in real time, ensuring that complications never arise in the first place.

Gone are the risks and uncertainties associated with outdated drainage systems from the 19th century. Through randomized trials with 160 flushed patients, Haermonics has achieved remarkable results with zero unnecessary reoperations. Led by heart surgeon Dave Koolbergen, Haermonics has already conducted extensive clinical validation with 340 patients, demonstrating a 59% reduction in blood loss and no reoperations.

By 2023, Haermonics plans to launch the only solution on the market that prevents post-operative heart surgery complications. Join the journey by sharing your email address to receive important milestones and developments from Haermonics. Embodying expertise, discipline, and creativity, Haermonics is dedicated to improving patient recovery, quality of life, and reducing hospital and infrastructure costs